Loading stock data…
NewcelX Ltd (NCEL)
$3.25-0.10 (-2.99%)
Market ClosedLast close Sep 8
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NewcelX Ltd. in the Healthcare sector is trading at $3.25 with a market capitalization of $17M. Wall Street consensus targets $23.00 (1 analysts), implying a +607.7% move over the next 12 months. The stock is currently near its 52-week low of $1.83, remaining 4.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +607.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|
| Total Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Income | — | — | — | — |
| Net Income | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.47M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
4,281
Recent News
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX Ltd. reported its 2025 financial results, with leadership emphasizing a "transformative year" marked by merger completion, balance sheet improvements, and progress in its lead Type 1 diabetes program, NCEL-101. Ronen Twito, executive chairman and CEO, said the company is positioning NCEL-101, developed in partnership with Eledon Pharmaceuticals Inc., as its primary long-term value driver. Twito added that the company's stem cell-derived islet platform, combined with targeted immune prote
Despite NewcelX's Pullback, Insiders Still Gained ₪136k
Insiders who bought NewcelX Ltd. ( NASDAQ:NCEL ) in the last 12 months may probably not pay attention to the stock's...
Owning 58% in NewcelX Ltd. (NASDAQ:NCEL) means that insiders are heavily invested in the company's future
Key Insights NewcelX's significant insider ownership suggests inherent interests in company's expansion 58% of the...